Proteomics International Laboratories (ASX: PIQ) has secured Canadian patent protection for PromarkerEso, its first-in-class blood test for the early detection of esophageal adenocarcinoma.
The granted patent (Canadian Patent No. 2967869), titled "Glycoprotein Biomarkers for Esophageal Adenocarcinoma and Barrett's Esophagus and Uses Thereof," protects the company's proprietary technology in Canada until Nov. 17, 20235 and supports its commercialisation strategy in North America, including direct sales, licensing, and partnership opportunities.
PromarkerEso is designed to detect EAC in its early stages, a critical need given that up to 90% of cases are currently diagnosed late, with a median survival of less than one year.
EAC is strongly associated with chronic acid reflux, which affects an estimated 20% of the US population.